Kymera Therapeutics: The Biotech Company Is Taking on Billion-Dollar Markets with Targeted Protein Destruction

Through targeted protein degradation, Kymera utilizes a biological recycling system that completely destroys harmful proteins rather than merely blocking them. The business model generates revenue through lucrative partnerships with pharmaceutical giants such as Sanofi, which help finance development costs through milestone payments and upfront payments. By focusing on proteins in immunology and oncology that have been difficult to treat to date, the company is targeting multi-billion markets with enormous blockbuster potential. In...